依拉戈利对子宫内膜异位症相关疼痛所致工作损失的影响:基于两项III期临床试验结果的估计
本文为Elaris I和II两项III期试验的事后分析,纳入有工作的18-49岁中重度子宫内膜异位症相关疼痛女性,随机接受安慰剂、依拉戈利150 mg每日一次或200 mg每日两次治疗6个月。与安慰剂相比,依拉戈利减少缺勤和出勤主义,改善生产力并估计节省费用。
要点
- 与安慰剂相比,依拉戈利150 mg每日一次和200 mg每日两次均减少缺勤和出勤主义,总工作损失改善。
- 依拉戈利150 mg每日一次组总工作每周增加>2小时,200 mg每日两次组增加>4小时。
- 估计6个月治疗费用节省:150 mg每日一次>1500美元,200 mg每日两次>3300美元。
核心结论
- 与安慰剂相比,依拉戈利治疗中重度子宫内膜异位症相关疼痛可减少缺勤并改善有工作女性的生产力,应可带来费用节省。
研究设计与样本
- Elaris I和II两项III期临床试验的事后分析,参与者随机接受6个月安慰剂、依拉戈利150 mg每日一次或200 mg每日两次治疗。
- 分析纳入EM-I有工作的参与者n=672和EM-II有工作的参与者n=626。
主要发现
- 基线至第3个月,与安慰剂组相比,依拉戈利150 mg每日一次组总工作每周增加>2小时(EM-I,2.20±1.03;EM-II,2.65±1.14)。
- 与安慰剂组相比,依拉戈利200 mg每日两次组总工作每周增加>4小时(EM-I,4.91±1.04;EM-II,4.64±1.14)。
- 缺勤和出勤主义均减少,但大部分增益来自出勤主义减少。
- 依拉戈利治疗6个月后估计费用节省:150 mg每日一次>1500美元,200 mg每日两次>3300美元。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the impact of elagolix on work loss due to endometriosis-associated pain. DESIGN: Post hoc analysis of data from the Elaris I and II clinical trials. SETTING: Not applicable. PATIENT(S): Employed women ages 18-49 years with moderate-to-severe endometriosis-associated pain. INTERVENTION(S): In the two trials, participants were randomized to 6 months of treatment with placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day. MAIN OUTCOME MEASURE(S): Data on planned work hours, presenteeism, absenteeism, and total work loss (absenteeism + presenteeism) at baseline and month 3 were collected using the Health-Related Productivity Questionnaire. RESULT(S): This analysis included employed participants from EM-I (n = 672) and EM-II (n = 626). Between baseline and month 3, compared with participants treated with placebo, participants treated with elagolix 150 mg once a day gained > 2 hours total work/week (EM-I, 2.20 ± 1.03; EM-II, 2.65 ± 1.14). Participants treated with 200 mg twice a day gained > 4 hours total work/week (EM-I, 4.91 ± 1.04; EM-II, 4.64 ± 1.14). Both absenteeism and presenteeism were reduced, although most of the gain was due to reduced presenteeism. Estimated cost savings after 6 months of treatment with elagolix were > $1,500 U.S. at 150 mg once a day and > $3,300 U.S. at 200 mg twice a day. CONCLUSION(S): Compared with placebo, treating moderate-to-severe endometriosis-associated pain with elagolix reduced absenteeism and improved productivity in employed women, which should result in cost savings. CLINICAL TRIAL NUMBER(S): NCT01620528 (EM-I) and NCT01931670 (EM-II).
引用
- Pokrzywinski RM, Soliman AM, Chen J, et al. Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials. Fertil Steril. 2019. PMID: 31227284. doi:10.1016/j.fertnstert.2019.04.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。